Direct oral anticoagulants (DOACs) are commonly used for the prevention of thrombosis in several cardiovascular contexts, including stroke prevention in patients with atrial fibrillation (AFib) and primary prevention, acute treatment or extended-duration secondary prevention of venous thromboembolism. In the November issue of Cardiology magazine, learn about the common regimens, appropriate use and uncertain circumstances related to dose-reduced DOACs. Read the full article.